We are a legal tech company who are building Archii - an AI company secretary that automatically finds and organizes your legal and financial documents, while providing you business intelligence based on those documents.  We are a group of lawyers, document experts and software developers - several of us with a focus on machine learning and NLP. Together we are building a world-class AI software. Visit Archii.ai and read more about our mission and see our team. To create a great product, we need the right people on board. We are highly collaborative and always encourage people to speak out their mind. As a growing startup, we take care of our company culture in all our HR initiatives and introduce to every new comer how is to work at Archii.From day one, there is room for creativity, passion and impact. We do enjoy challenges and be challenged. We encourage our employees to find solutions to problems and take initiative to make things happen in our company.

Saninudge is a healthcare technology company, our mission is to eliminate Hospital Acquired Infections, a leading cause of death in the entire world. We design and market the only comprehensive hand-hygiene performance system which combines sensor networks with nudging technology to provide a complete, long-term and cost-effective hand hygiene system for healthcare institutions. You should apply for a job at Sani nudge if you want to have a job in a fast moving, intense company with the smartest people in the healthcare industry. We focus on reducing stress and improve quality of experience for all working on the project. Company facts We have more than 5,000 active sensors installed in hospitals. They have registered +2,000,000 hand sanitations and +100,000 patient interactions. They help +1,000 healthcare workers ensure proper hand hygiene compliance. We help hospitals and nursing homes in 7 European countries have clean hand when treating patients. We work with the largest healthcare companies in the world

Venture Cup’s mission is to identify and develop the talents and technology of tomorrow. We are an association of the Danish universities and we work to promote entrepreneurship among university students. We host two national startup competitions annually, a University Startup World Cup with teams from all over the world, Scandinavia’s largest Startup Mentors program for university students and the program Nordic HealthTech Talents with the support of Novo Nordisk Foundation.

My4 is a social betting platform for true football fans!Our ambition is to revolutionize the way we bet on sports by creating superior peer-to-peer betting experiences. The My4 app launched in Denmark April 2017 and has since maintained a steady presence among the 20 most popular sports apps. In 2018, we're looking to expand to the UK and potentially other markets.We are located in the vibrant startup hub Founders House, Copenhagen, where we share offices with more than 30 other tech-startups.

Pinstriped is a powerful SaaS product which has just launched from Beta, already has paying users and with numbers growing daily. We currently have a macOS app and are building out a web app.We make it easy for the person calling the meeting to take ownership, prepare an agenda and ensure the meeting is decision-focused, instead of discussion-focused. Pinstriped is your easy way to prepare and run successful meetings

Dixa is a global customer service tech company on a mission to create friendships between brands and their customers, break down technology silos and eliminate bad customer service.Dixa is a truly international company with 14+ nationalities working together in the heart of Copenhagen and with offices in London, Berlin and Kiev. With customers in 20+ countries, Dixa has experienced incredible growth since it’s launch in 2018, quickly becoming one of Scandinavia’s fastest growing SaaS companies.

NORD.investments blev stiftet, som en reaktion mod bankernes dyre og komplekse investeringsprodukter. Vi er en fintech virksomhed, der i samarbejde med Saxo Bank, tilbyder en nem og enkel investeringsløsning. Vi søger løbende talenter til vores team, så hold dig ikke tilbage med at tage kontakt til os, hvis du vil med på rejsen. Mød os på NORD.investments!

Describe your startup, what problem you are solving and why. Describe your startup, what problem you are solving and why. Describe your startup, what problem you are solving and why. Describe your startup, what problem you are solving and why. Describe your startup, what problem you are solving and why. Describe your startup, what problem you are solving and why. Describe your startup, what problem you are solving and why.

Add a description between 300 and 4000 charactersAdd a description between 300 and 4000 charactersAdd a description between 300 and 4000 charactersAdd a description between 300 and 4000 charactersAdd a description between 300 and 4000 charactersAdd a description between 300 and 4000 charactersAdd a description between 300 and 4000 characters

SoilSense is an agro-technology company that works to solve one of the grandest climate challenges of this century - water scarcity. We are driven by the ambition of making a real difference in the world. Today, more than 70% of all available freshwater is used for watering crops. This puts farming at the center of attention if we are to solve the global challenge of water scarcity. SoilSense offers an affordable soil sensor and software solution that helps farmers optimize the growth of their crops, by intelligently recommending when and where to water. SoilSense-farmers reduce water usage and increase their yield. Our company is born global with systems deployed in Peru, Kenya, and Denmark. Since 2018 we have worked to develop our product and market fit, and in 2020 we started selling our solution to the first base of customers. Our focus in 2021 will be on maturing our hardware for production and distribution, adding advanced software features to our platform, and scaling sales to European markets.

Founded in 2015 by experienced entrepreneurs, we quickly gained traction as a Y Combinator funded Company – one of the most prestigious startup-accelerators in the world. Since then, we have grown from a Startup-challenger to becoming an industry leader within our area. GetAccept is an All-in-One Platform for B2B Sales and our Vision is to become the platform where every B2B business happens, in a natural way. We just raised 120Million to rock on - wanna dance?

Mendonca Biomed is an early stage life science startup with the aim to develop and validate novel biomarker for the early detection of viral infections in blood with an affordable yet simple detection method that can be universally applied. The company was originally founded by myself Kevin Mendonca in India based on his 15 years of accumulative research knowledge. Preliminary data on the utility of viral miRNA biomarkers for the screening of blood for transfusion transmitted viral infections, which are potentially superior to the currently available markers, and a simplified assay that is cost effective and can be universally adapted, were developed in India. However, due to an innate lack of infrastructure and funding opportunities in India, I applied for the startup Denmark program to move the company to the medicon valley. I recently moved to Demark, registered a privately owned company and currently in pursue of funding to validate the viral miRNA biomarkers for the early detection of HIV, HBV and HCV in donated blood. Around the world, more than 92 million blood donations are collected every year. Screening of donated blood and derived products, for HIV, HBV and HCV is mandatory worldwide. Screening is a key safety measure in protecting recipients from transfusion transmitted infections, especially in developing nations in Africa and Asia, where the donated blood is not processed because of high costs and lack of infrastructure. Moreover, in emergency situation like natural calamities, disasters and sudden outbreaks, the currently available methods are inadequate for on-site screening. Serological testing (antigen and antibody detection assays) have historically been the foundation of blood screening but with huge drawbacks of long window periods. Newer strategies like the PCR based amplification viral genomic DNA/RNA in blood have helped shorten the window period but have not eliminated it. PCR assays have also been known to fail in low viremia and/or suboptimal amplification efficiency. They are far more expensive than the serological assay, requires expertise, specialized equipment and a molecular biology setup, which is not available in the resource poor settings of the developing countries. Our solution is to develop and validate novel viral miRNA biomarkers that have the potential to further reduce the window period and use the unique characteristics of these biomarkers to develop a simple, multiplex (3 in 1), inexpensive probe hybridization assay that can be universally utilized in all settings and conditions. Viral miRNA molecules are easy to validate as biomarkers since the presence of vmiRNA’s is a definite indicator of infected cells. Benefit: Multiplex 3 in 1 test. Method as simple to perform as the serological assay with the benefits of a molecular assay. Can be adapted in any setting, even in the field and low resource conditions in developing nations. Potentially, lower window period of detection compared to any biomarkers that are available in the market currently. Value: High throughput, lower turnover time with lower chances of human error. Advantages of a molecular assay with the simplicity and affordability of a serological assay. Does not require specialized setup, infrastructure and highly trained technicians. Potentially, could detect the infections faster than any other tests in the market, lowering the risk of transfusion transmission. Once this platform has been validated, the product line can be expanded to cover all commercially viable viral infections. A HPV assay based on this platform, for example, could be a potential replacement for the invasive PAP test, and can be performed during a routine blood test. The platform can be further adapted to screen for novel viral infections like SARS, MERS, ZIKA etc. It can be also be developed to screen and control other sporadic outbreaks the like Dengue, Chikungunya etc.

For a quick intro pls see: https://drive.google.com/file/d/168TTZsNef43Awmxz3iALMhx2saVk5ihe/view?usp=sharing The problem & the idea Data may be the driver for change, improvement and understanding, in many sectors, amongst these also healthcare. Patient data is an important creator of knowledge both on an individual level but also on a group, regional or country level. On an individual level, patient data may support and build the clinical decisions, it may provide more efficient treatment, both in regard to time and economy and secure that knowledge about the individual is transferred fast and unbiased to the healthcare staff. For the patient, sharing of his/her data will secure a better understanding of the needs and support better diagnosis and treatment. Patient data are collected and noticed in some form in most countries, either on paper or electronically. Many countries have some sort of an electronic patient journal, either on a country level, regionally or locally. However, many countries also still use pen & paper. This challenges the storage and continuity of data collection and transfer. Patient data records in electronic form reduces the risk of losing valuable data but also allows the data to be shared if needed. The acknowledgement of the importance on several levels of having patient data and the absence of a central, regional or local electronic patient data recording system in Sub-saharan African countries (the target region) initiated the idea of looking at how it would be possible to collect and make patient data readily available for treatment, benefitting both patient and caregiver, and in a bigger perspective, for research and strategic healthcare initiative planning. During small initial market and possibility investigations the idea of creating a patient owned electronic healthdata journal app arose. Mobiletechnology is both greatly advantaged and outspread in the target region and the number of mobile consumers are increasing every year. It was and is anticipated, that the possibility of having a central system is, due to structural and financial reasons, not a possibility but to empower the patient with the ownership of own data through an app seemed a possibility. It is important to underline that data must be generated from the healthcare provider and then fed into the patientjournal at the site of the consultation. The idea is to have the most relevant data collected and stored in the app, ie. medication, allergies, blood type, diagnosis and immunizations. The data that will go into the app is transferred from a healthcare provider at the site of the healthcare visit, eg a clinique, hospital, other. That means that the healthcare provider must have access to a tablet or smartphone containing the healthcare provider app which connects to the patients healthcare data app at the visit. Also any healthcare provider with the app will followingly get access to the data from the patient by connecting (and by being given access by the patient) to get patients healthdata app. So, in summary the basic idea is to provide all citizens with a tool that will help them keep track of their most important healthcare related data including completed and planned treatments, diagnosis, tests, allergies etc. The idea is further that the data is owned by the citizens/patients, and not by the non-existing national or any hospital specific system. Upon each contact with the healthcare personnel the patient's information is updated by the healthcare personnel (e.g. symptoms, diagnosis, tests, treatment, next visit etc.) The basic idea/assumption is that no national healthcare system will be developed in near or short-term future, and that a personally owned "electronic patient journal" can have a significant positive impact on the quality of treatments because of a more complete picture of the patient is available at the time, when a diagnosis and treatment is to be decided.

NUKIGA faciliterer værdiskabende partnerskaber mellem iværksættere, virksomheder og studerende. Vi udvikler et virtuelt væksthus, og vi skaber ny viden om Grønland i Danmark gennem en række kulturelle projekter. Dialog og partnerskaber opstår, når mennesker mødes enten fysisk eller online. Vores arbejde er derfor funderet i både fysiske såvel som online events og projekter.

Jobstar is a recruitment platform that changes the way companies find candidates today, and not least makes it easier and much more intuitive for the candidates. The platform is based on a philosophy of anonymity and an easy gamification approach for candidates. We advocate more diversity and equality in the recruitment process resulting in less stress, more effective and respectful dialogue between candidates and companies. Candidates no longer have to search for job - the job finds you.